Pub Date : 2025-08-07DOI: 10.23736/S2784-8671.25.08321-5
Gaetano Licata, Luca Damiani, Giulia Briatico, Giuseppe Argenziano, Eugenia V DI Brizzi, Camila Scharf, Graziella Babino, Elisabetta Fulgione, Caterina M Giorgio
{"title":"Intralesional rifampicina and triamcinolone acetonide for mild-to-moderate hidradenitis suppurativa.","authors":"Gaetano Licata, Luca Damiani, Giulia Briatico, Giuseppe Argenziano, Eugenia V DI Brizzi, Camila Scharf, Graziella Babino, Elisabetta Fulgione, Caterina M Giorgio","doi":"10.23736/S2784-8671.25.08321-5","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08321-5","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-07-02DOI: 10.23736/S2784-8671.25.08107-1
Filomena Russo, Donatella Sordi, Anna R Giampetruzzi, Anna Dattolo, Sabatino Pallotta, Enrico Scala, Siavash Rahimi, Ornella DE Pità, Barbara Cocuroccia
{"title":"Erythrodermic atopic dermatitis successfully treated with upadacitinib.","authors":"Filomena Russo, Donatella Sordi, Anna R Giampetruzzi, Anna Dattolo, Sabatino Pallotta, Enrico Scala, Siavash Rahimi, Ornella DE Pità, Barbara Cocuroccia","doi":"10.23736/S2784-8671.25.08107-1","DOIUrl":"10.23736/S2784-8671.25.08107-1","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"374-376"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hair and beyond: the experience of the Dermatology Department at the University of Rome La Sapienza.","authors":"Sandra Giustini, Alfredo Rossi, Luigina Divona, Emanuele Miraglia, Vincenzo Roberti, Roberto Porciello, Gemma Caro, Donato DI Nunno, Elisa Moliterni, Stefano Calvieri","doi":"10.23736/S2784-8671.25.08172-1","DOIUrl":"10.23736/S2784-8671.25.08172-1","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"301-303"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-06-23DOI: 10.23736/S2784-8671.25.08202-7
Michele Lanzetti, Filippo Toaiari, Emanuele M Cipollini, Daniela Massi, Ilaria C Galli, Emiliano Antiga
{"title":"Unveiling the bridge between neutrophilic and autoinflammatory spectrum. Good response to old but gold colchicine in a complex clinical association of Sweet Syndrome with psoriasis and hidradenitis suppurativa under treatment with ixekizumab.","authors":"Michele Lanzetti, Filippo Toaiari, Emanuele M Cipollini, Daniela Massi, Ilaria C Galli, Emiliano Antiga","doi":"10.23736/S2784-8671.25.08202-7","DOIUrl":"10.23736/S2784-8671.25.08202-7","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"382-383"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-04-28DOI: 10.23736/S2784-8671.25.08200-3
Lorenzo Scaramuzzino, Luigi Coronella, Giuseppe Lauletta, Nello Tommasino, Fabrizio Martora, Laura Marano, Maria C Annunziata
{"title":"Recalcitrant isotretinoin-induced acne fulminans successfully treated with oral dapsone.","authors":"Lorenzo Scaramuzzino, Luigi Coronella, Giuseppe Lauletta, Nello Tommasino, Fabrizio Martora, Laura Marano, Maria C Annunziata","doi":"10.23736/S2784-8671.25.08200-3","DOIUrl":"10.23736/S2784-8671.25.08200-3","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"381-382"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-04-09DOI: 10.23736/S2784-8671.25.08220-9
Seognjin Ju, Yoon-Seob Kim
{"title":"Resolution of severe atopic dermatitis but not concurrent vitiligo following dupilumab in children: case report of two siblings.","authors":"Seognjin Ju, Yoon-Seob Kim","doi":"10.23736/S2784-8671.25.08220-9","DOIUrl":"10.23736/S2784-8671.25.08220-9","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"385-386"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-04-03DOI: 10.23736/S2784-8671.25.08197-6
Riccardo Balestri, Davide Geat, Francesca Rivieri, Annalisa Pedrolli, Ilaria Palmieri, Enza M Valente, Stefania Termine, Aldo Naselli, Laura Nai Fovino, Danila D'Onofrio, Laura Rizzoli
{"title":"Ectodermal dysplasia/skin fragility syndrome: first Italian case due to a new homozygous mutation in the PKP1 gene.","authors":"Riccardo Balestri, Davide Geat, Francesca Rivieri, Annalisa Pedrolli, Ilaria Palmieri, Enza M Valente, Stefania Termine, Aldo Naselli, Laura Nai Fovino, Danila D'Onofrio, Laura Rizzoli","doi":"10.23736/S2784-8671.25.08197-6","DOIUrl":"10.23736/S2784-8671.25.08197-6","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"379-381"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.23736/S2784-8671.25.08222-2
Federica Scarfì, Michele Lanzetti, Serena Rosati, Franca Taviti
{"title":"Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.","authors":"Federica Scarfì, Michele Lanzetti, Serena Rosati, Franca Taviti","doi":"10.23736/S2784-8671.25.08222-2","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08222-2","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 4","pages":"386-388"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Role of onabotulinumtoxinA in treating platysma prominence asymmetry and cervical pain: case report of two patients.","authors":"Ilaria Proietti, Agnieszka Dybala, Emanuele Amore, Guida Stefania, Concetta Potenza","doi":"10.23736/S2784-8671.25.08208-8","DOIUrl":"10.23736/S2784-8671.25.08208-8","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"384-385"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01Epub Date: 2025-05-08DOI: 10.23736/S2784-8671.25.08144-7
Aditya K Bubna, Vinayak Viplav
Omalizumab is a humanized monoclonal IgG1 antibody approved by the US-FDA for the treatment of chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines. The aim of this review is to outline the utility of omalizumab in all types of urticarias, as well as other off-label dermatological disorders. A comprehensive literature search was conducted to identify studies evaluating the utility of omalizumab in dermatology. Databases searched included PubMed, Medline, and Embase. All original studies including case reports, case series and clinical trials were included if they were full-text, involved a dermatologic disorder treated with omalizumab and published in English. Articles were excluded if they were conference abstracts, non-clinical reports, or invitro studies. Apart from CSU, the efficacy of omalizumab has been demonstrated in atopic dermatitis (AD), bullous pemphigoid (BP), hyper IgE syndrome (HIES), mastocytosis, and Kimura's disease (KD), with the level of evidence varying for each disorder. Besides, in anecdotal reports, the benefits of omalizumab in TEN and Netherton Syndrome has been highlighted. Omalizumab offers a promising therapeutic option for a variety of dermatologic disorders beyond CSU. Further research is needed to optimize treatment protocols and establish definitive guidelines for omalizumab use in these conditions to facilitate quicker disease remission, improved safety, and reduced reliance on conventional immunosuppressants. However, the high cost of omalizumab remains a significant barrier for its widespread use in developing countries.
{"title":"Omalizumab: a broader role in dermatology? Evidence and the road ahead.","authors":"Aditya K Bubna, Vinayak Viplav","doi":"10.23736/S2784-8671.25.08144-7","DOIUrl":"10.23736/S2784-8671.25.08144-7","url":null,"abstract":"<p><p>Omalizumab is a humanized monoclonal IgG1 antibody approved by the US-FDA for the treatment of chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines. The aim of this review is to outline the utility of omalizumab in all types of urticarias, as well as other off-label dermatological disorders. A comprehensive literature search was conducted to identify studies evaluating the utility of omalizumab in dermatology. Databases searched included PubMed, Medline, and Embase. All original studies including case reports, case series and clinical trials were included if they were full-text, involved a dermatologic disorder treated with omalizumab and published in English. Articles were excluded if they were conference abstracts, non-clinical reports, or invitro studies. Apart from CSU, the efficacy of omalizumab has been demonstrated in atopic dermatitis (AD), bullous pemphigoid (BP), hyper IgE syndrome (HIES), mastocytosis, and Kimura's disease (KD), with the level of evidence varying for each disorder. Besides, in anecdotal reports, the benefits of omalizumab in TEN and Netherton Syndrome has been highlighted. Omalizumab offers a promising therapeutic option for a variety of dermatologic disorders beyond CSU. Further research is needed to optimize treatment protocols and establish definitive guidelines for omalizumab use in these conditions to facilitate quicker disease remission, improved safety, and reduced reliance on conventional immunosuppressants. However, the high cost of omalizumab remains a significant barrier for its widespread use in developing countries.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"323-336"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号